Floatz logo

Inno-206

Doxorubicin Induced Cardiomyopathy

Tanta UniversityPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Doxorubicin Induced Cardiomyopathy cohort.

Asset / SponsorPhaseRating
Lipitor
Damanhour University
Phase 2B
Dapagliflozin
Tanta University
Phase 2CCC
Pentoxifylline
Tanta University
Phase 2CCC
Micardis®
Tanta University
Phase 1/2CC
Eovist
University of Campinas, Brazil
N/AD
Montelukast
Damanhour University
N/AD

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →